查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
微生物基因体治疗的全球市场 - 产业规模，占有率，趋势，机会，预测:各类型，各用途，各地区(2017年～2027年)
市场调查报告书
商品编码
1152250

微生物基因体治疗的全球市场 - 产业规模，占有率，趋势，机会，预测:各类型，各用途，各地区(2017年～2027年)

Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type, By Application, By Region
出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球微生物基因体治疗市场，预计在预测期间内的2023年～2027年完成惊人的成长。

由于苯酮尿症，肝性脑病变，C.difishiru感染疾病(CDI)等疾病的盛行率上升造成正确迅速治疗的必要性，预期在预测期间内促进全球微生物基因体治疗市场成长。

使用了还有微生物基因体的治疗方法的发现是新的领域，根据全球的学者，研究人员，各种生物科技、製药公司关注，微生物基因体治疗相关的研究、临床试验这几年大幅度增加着。预计这个，生出在预测期间内预计的市场成长有利的机会。

本报告提供全球微生物基因体治疗市场相关调查分析，各市场区隔、各地区的市场规模、占有率预测，市场动态，企业简介等系统性资讯。

目录

第1章 产品概要

第2章 调查手法

第3章 摘要整理

第4章 COVID-19对全球微生物基因体治疗市场的影响

第5章 VOC(客户的迴响)

第6章 临床试验分析

第7章 全球微生物基因体治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类型(FMT和微生物基因体药)
    • 各用途(C.difishiru感染疾病，克隆氏症，发炎性肠道疾病，糖尿病，其他)
    • 各地区
    • 各企业(2021年)
  • 产品市场地图

第8章 北美的微生物基因体治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类型
    • 各用途
    • 各国
  • 北美:各国分析
    • 美国
    • 墨西哥
    • 加拿大

第9章 欧洲的微生物基因体治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类型
    • 各用途
    • 各国
  • 欧洲:各国分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第10章 亚太地区的微生物基因体治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类型
    • 各用途
    • 各国
  • 亚太地区:各国分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第11章 南美的微生物基因体治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类型
    • 各用途
    • 各国
  • 南美:各国分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第12章 中东、非洲的微生物基因体治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类型
    • 各用途
    • 各国
  • MEA:各国分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国

第13章 市场动态

  • 促进因素
  • 课题

第14章 市场趋势与开发

第15章 竞争情形

  • 4D Pharma plc
  • Enterome SA
  • Finch Therapeutics Group, Inc.
  • Vedanta Bioscience, Inc.
  • Seres Therapeutics, Inc.
  • Microbiotica Limited
  • Destiny Pharma plc
  • Taisho Pharmaceutical Holdings Co., Ltd.
  • AOBiome Therapeutics, Inc.
  • Ferring Pharmaceuticals SA

第16章 策略性建议

简介目录
Product Code: 12867

The global microbiome therapeutics market is anticipated to witness an impressive growth during the forecast period, 2023-2027. This can be ascribed to the growing prevalence of diseases like phenylketonuria, hepatic encephalopathy, C. difficile infection (CDI), among others and requirement for a precise and faster treatment. This in turn is expected to drive the growth of global microbiome therapeutics market during the forecast period. Additionally, finding therapeutic solutions using microbiome is an emerging field and is attracting the attention of academicians, researchers, and various biotechnology & pharmaceutical companies across the globe. The research, clinical trials related to microbiome therapeutics have significantly increased over the years. According to clinicaltrials.gov, there are around 188 clinical trials registered on its portal related to microbiome therapeutics. This in turn is expected to create lucrative opportunities for the market growth during the forecast period.

Increasing Focus on Human Microbiome Therapeutics Development

The increase prevalence of different types of diseases, failure of current treatment options in providing accurate cure, among others have led to a shift towards alternative therapeutics such as microbiome therapeutics. Being an emerging field, microbiome therapeutics is receiving the attention of research fraternity across the globe. As a result of this a lot of drug discovery and development is happening. As of now there is no approved product and major products are in early stages of clinical trials, in phases I and II. However, companies are advancing their research and may be in the near future an approved microbiome therapeutic product will be available in the market. For instance, in 2021, Seres Therapeutics, Inc. announced data of SER-109, released from its Phase 3 ECOSPOR III study. The pipeline drug is under investigation as an oral therapy for recurring C. difficile infection with an anticipated launch in the first half of 2023.

Growing Funding Activities, Collaborations

The growing collaborations, partnerships, mergers & acquisitions and other strategies followed by various biotechnology & pharmaceutical companies in order to develop a potential microbiome therapeutics is expected to support the market growth in the coming years. For instance, in March 2019, AstraZeneca Plc., collaborated with Seres Therapeutics, Inc. to determine the effect of microbiome environment in a patient undergoing immunotherapy for cancer. Similarly in 2016, AbbVie Inc. entered into a partnership with Synlogic, Inc. for the development of drug for inflammatory bowel disorders. Additionally, increasing funding by different government and non-government organizations across the globe to support research & development activities related to microbiome therapeutics is expected to create lucrative opportunities for the market growth in the next few years. For instance, in 2016, the United States federal government announced USD 121 million for Microbiome Initiative, to provide and coordinate funds for microbiome research.

Market Segmentation

The global microbiome therapeutics market can be segmented into by type, by application, by region, and by company. Based on by type, the market can be divided into FMT and microbiome drugs. Based on application, the market can be categorized into C. Difficile, crohn's disease, inflammatory bowel disease, diabetes, and others. Regionally, North America dominated the market followed Europe, Asia Pacific, South America and Middle East & Africa. In terms of country, the United States is dominating the overall global microbiome therapeutics market. This can be ascribed to the increasing funding activities in the United States. For instance, the total biotechnology companies funding in the United States stood around USD99.4 billion.

Market Players

4D Pharma plc, Enterome SA, Finch Therapeutics Group, Inc., Vedanta Bioscience, Inc., Seres Therapeutics, Inc., Microbiotica Limited, Destiny Pharma plc, Taisho Pharmaceutical Holdings Co., Ltd., AOBiome Therapeutics, Inc., Ferring Pharmaceuticals SA are some of the leading players operating in the global microbiome therapeutics market.

Report Scope:

In this report, global microbiome therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Microbiome Therapeutics Market, By Type:

  • FMT
  • Microbiome Drugs

Microbiome Therapeutics Market, By Application:

  • C. Difficile
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Diabetes
  • Others

Microbiome Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Microbiome Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Microbiome Therapeutics Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Microbiome Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (FMT v/s Microbiome Drugs)
    • 7.2.2. By Application (C. Difficile, Crohn's Disease, Inflammatory Bowel Disease, Diabetes, Others)
    • 7.2.3. By Region
    • 7.2.4. By Company (2021)
  • 7.3. Product Market Map

8. North America Microbiome Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Microbiome Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Mexico Microbiome Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Canada Microbiome Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application

9. Europe Microbiome Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Microbiome Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Germany Microbiome Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. United Kingdom Microbiome Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
    • 9.3.4. Italy Microbiome Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Application
    • 9.3.5. Spain Microbiome Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By Application

10. Asia-Pacific Microbiome Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Microbiome Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. India Microbiome Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. South Korea Microbiome Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
    • 10.3.4. Japan Microbiome Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Application
    • 10.3.5. Australia Microbiome Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Application

11. South America Microbiome Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Application
    • 11.2.3. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Microbiome Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Argentina Microbiome Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
    • 11.3.3. Colombia Microbiome Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application

12. Middle East and Africa Microbiome Therapeutics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Application
    • 12.2.3. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Microbiome Therapeutics Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type
        • 12.3.1.2.2. By Application
    • 12.3.2. Saudi Arabia Microbiome Therapeutics Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type
        • 12.3.2.2.2. By Application
    • 12.3.3. UAE Microbiome Therapeutics Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type
        • 12.3.3.2.2. By Application

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. 4D Pharma plc
  • 15.2. Enterome SA
  • 15.3. Finch Therapeutics Group, Inc.
  • 15.4. Vedanta Bioscience, Inc.
  • 15.5. Seres Therapeutics, Inc.
  • 15.6. Microbiotica Limited
  • 15.7. Destiny Pharma plc
  • 15.8. Taisho Pharmaceutical Holdings Co., Ltd.
  • 15.9. AOBiome Therapeutics, Inc.
  • 15.10. Ferring Pharmaceuticals SA

16. Strategic Recommendations